Pulmonary Aspergillosis

ABSTRACT

As the population of patients with prolonged neutropenia, those receiving hematopoietic stem cell transplantation or lung transplantation, or those with human immunodeficiency virus or acquired immunodeficiency syndrome continues to increase, the rising incidence of pulmonary aspergillosis is unlikely to diminish. Aspergillus species are ubiquitous in nature, have no geographic predilection, and the spectrum of disease they cause is myriad, ranging from noninvasive disease with colonization to disseminated disease with an associated high mortality rate. The extent of disease is thus largely responsible for both the choice and the duration of antifungal therapy. Recent years have seen an expansion of antifungal agents, with efficacy against Aspergillus requiring an understanding of the full spectrum of disease for them to be used appropriately. Diagnosis is often difficult because existing tests lack desired sensitivity or specificity.

Pulmonary aspergillosis - voriconazole - Aspergillus fumigatus

REFERENCES

• 1 Walsh T J, Anaissie E J, Denning D W, Herbrecht R et al.. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America (IDSA).  Clin Infect Dis. 2008;  46(3) 327-360
• 2 Patterson T F, Kirkpatrick W R, White M et al.. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group.  Medicine. 2000;  79 250-260
• 3 Anaissie E J, Stratton S L, Dignani M C et al.. Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study.  Clin Infect Dis. 2002;  34 780-789
• 4 Warris A, Voss A, Abrahamsen T G, Verweij P E. Contamination of hospital water with Aspergillus fumigatus and other molds.  Clin Infect Dis. 2002;  34 1159-1160
• 5 Torres H A, Rivero G A, Lewis R E et al.. Aspergillosis caused by non-fumigatus Aspergillus species: risk factors and in vitro susceptibility compared with Aspergillus fumigatus .  Diagn Microbiol Infect Dis. 2003;  46 25-28
• 6 Patterson J E, Peters J, Calhoon J H et al.. Investigation and control of aspergillosis and other filamentous fungal infections in solid organ transplant recipients.  Transpl Infect Dis. 2000;  2 22-28
• 7 Paterson D L, Singh N. Invasive aspergillosis in transplant recipients.  Medicine. 1999;  78 123-138
• 8 Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy.  N Engl J Med. 2001;  344 1099-1100
• 9 Cohen M S, Isturiz R E, Malech H L et al.. Fungal infection in chronic granulomatous disease: the importance of the phagocyte in defense against fungi.  Am J Med. 1981;  71 59-66
• 10 Denning D W. Aspergillosis in “nonimmunocompromised” critically ill patients.  Am J Respir Crit Care Med. 2004;  170 580-581
• 11 Gerson S L, Talbot G H, Hurwitz S et al.. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia.  Ann Intern Med. 1984;  100 345-351
• 12 Wald A, Leisenring W, van Burik J A, Bowden R A. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation.  J Infect Dis. 1997;  175 1459-1466
• 13 Denning D W. Invasive aspergillosis.  Clin Infect Dis. 1998;  26 781-803
• 14 Greene R. The radiological spectrum of pulmonary aspergillosis.  Med Mycol. 2005;  43(Suppl 1) S147-S154
• 15 Denning D W, Follansbee S E, Scolaro M et al.. Pulmonary aspergillosis in the acquired immunodeficiency syndrome.  N Engl J Med. 1991;  324 654-662
• 16 Kramer M R, Denning D W, Marshall S E et al.. Ulcerative tracheobronchitis after lung transplantation: a new form of invasive aspergillosis.  Am Rev Respir Dis. 1991;  144(3 Pt 1) 552-556
• 17 Binder R E, Faling L J, Pugatch R D, Mahasaen C, Snider G L. Chronic necrotizing pulmonary aspergillosis: a discrete clinical entity.  Medicine. 1982;  61 109-124
• 18 Gefter W B, Weingrad T R, Epstein D M, Ochs R H, Miller W T. “Semi-invasive” pulmonary aspergillosis: a new look at the spectrum of aspergillus infections of the lung.  Radiology. 1981;  140 313-321
• 19 Hope W W, Walsh T J, Denning D W. The invasive and saprophytic syndromes due to Aspergillus spp.  Med Mycol. 2005;  43(Suppl 1) S207-S238
• 20 Denning D W, Riniotis K, Dobrashian R, Sambatakou H. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review.  Clin Infect Dis. 2003;  37(Suppl 3) S265-S280
• 21 Lin S J, Schranz J, Teutsch S M. Aspergillosis case-fatality rate: systematic review of the literature.  Clin Infect Dis. 2001;  32 358-366
• 22 Greenberger P A. Allergic bronchopulmonary aspergillosis.  J Allergy Clin Immunol. 2002;  110 685-692
• 23 Stevens D A, Schwartz H J, Lee J Y et al.. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis.  N Engl J Med. 2000;  342 756-762
• 24 Munoz P, Alcala L, Sanchez Conde M et al.. The isolation of Aspergillus fumigatus from respiratory tract specimens in heart transplant recipients is highly predictive of invasive aspergillosis.  Transplantation. 2003;  75 326-329
• 25 Horvath J A, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis.  Am J Med. 1996;  100 171-178
• 26 Herbrecht R, Letscher-Bru V, Oprea C et al.. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients.  J Clin Oncol. 2002;  20 1898-1906
• 27 Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation.  Blood. 2001;  97 1604-1610
• 28 Verweij P E, Mennink-Kersten M A. Issues with galactomannan testing.  Med Mycol. 2006;  44(Suppl) 179-183
• 29 Odabasi Z, Mattiuzzi G, Estey E et al.. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome.  Clin Infect Dis. 2004;  39 199-205
• 30 Donnelly J P. Polymerase chain reaction for diagnosing invasive aspergillosis: getting closer but still a ways to go.  Clin Infect Dis. 2006;  42 487-489
• 31 Bates D W, Su L, Yu D T et al.. Mortality and costs of acute renal failure associated with amphotericin B therapy.  Clin Infect Dis. 2001;  32 686-693
• 32 Cornely O A, Maertens J, Bresnik M et al.. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).  Clin Infect Dis. 2007;  44 1289-1297
• 33 Eiden C, Peyriere H, Cociglio M et al.. Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database.  Ann Pharmacother. 2007;  41 755-763
• 34 Steinbach W J, Stevens D A. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis.  Clin Infect Dis. 2003;  37(Suppl 3) S157-S187
• 35 Herbrecht R, Denning D W, Patterson T F et al.. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.  N Engl J Med. 2002;  347 408-415
• 36 De Beule K, Van Gestel J. Pharmacology of itraconazole.  Drugs. 2001;  61(Suppl 1) 27-37
• 37 Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults.  Br J Clin Pharmacol. 2004;  57 218-222
• 38 Ullmann A J, Lipton J H, Vesole D H et al.. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.  N Engl J Med. 2007;  356 335-347
• 39 Cornely O A, Maertens J, Winston D J et al.. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.  N Engl J Med. 2007;  356 348-359
• 40 Bennett J E. Echinocandins for candidemia in adults without neutropenia.  N Engl J Med. 2006;  355 1154-1159
• 41 Marr K A, Boeckh M, Carter R A, Kim H W, Corey L. Combination antifungal therapy for invasive aspergillosis.  Clin Infect Dis. 2004;  39 797-802